Markets:

Overview

News

Currencies

International

Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

31.30 +0.04 (+0.11%)

Streaming Delayed Price Updated: 11:47 AM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM Investors ↗

May 13, 2025

CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A top pick for growth investors.

Via Chartmill

Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing? ↗

May 10, 2025

A fundamental analysis of (NASDAQ:CPRX): CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) showing high EPS and FCF growth while beating expectations

Via Chartmill

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

May 07, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Does CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) meet the Minervini criteria? ↗

May 07, 2025

A fundamental and technical analysis of (NASDAQ:CPRX): Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).

Via Chartmill

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s quality characteristics. ↗

May 01, 2025

A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Deserves Consideration as a Quality Investment.

Via Chartmill

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Strong Candidate for CAN SLIM Investors ↗

April 30, 2025

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Strong Candidate for CAN SLIM Investors

Via Chartmill

Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

April 30, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock? ↗

April 26, 2025

Based on fundamental and technical analysis of NASDAQ:CPRX we ask: Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Is a Standout High-Growth Stock in a Consolidation Phase.

Via Chartmill

Investors should take note of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a growth stock that remains attractively priced. ↗

April 24, 2025

CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced...

Via Chartmill

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

April 22, 2025

The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. ↗

April 21, 2025

A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects.

Via Chartmill

Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for high Growth Investing Strategies? ↗

April 18, 2025

A fundamental and technical analysis of (NASDAQ:CPRX): Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).

Via Chartmill

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for growth investors. Here's why. ↗

April 16, 2025

A fundamental analysis of (NASDAQ:CPRX): CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for growth investors. Here's why.

Via Chartmill

Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

April 08, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Why Mark Minervini may look into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) ↗

April 05, 2025

A fundamental and technical analysis of (NASDAQ:CPRX): Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing?

Via Chartmill

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday ↗

April 03, 2025

Via The Motley Fool

Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). ↗

March 31, 2025

A fundamental analysis of (NASDAQ:CPRX): Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing?

Via Chartmill

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is showing decent growth, but is still valued reasonably. ↗

March 28, 2025

CATALYST PHARMACEUTICALS INC could be undervalued. NASDAQ:CPRX is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.

Via Chartmill

Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing? ↗

March 25, 2025

A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.

Via Chartmill

Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? ↗

March 23, 2025

Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your...

Via Benzinga

For those who appreciate value investing, CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a compelling option with its solid fundamentals. ↗

March 21, 2025

Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a CANSLIM stock. ↗

March 06, 2025

A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for Growth Investing Strategies?

Via Chartmill

Looking for growth without the hefty price tag? Consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). ↗

March 06, 2025

CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced...

Via Chartmill

Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock? ↗

March 06, 2025

Based on a technical and fundamental analysis of NASDAQ:CPRX we are exploring the Growth Potential of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as It Nears a Breakout.

Via Chartmill

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

March 04, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing? ↗

March 04, 2025

A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing?

Via Chartmill

Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today ↗

February 27, 2025

The drugmaker confirmed there's a strong market for two of its treatments.

Via The Motley Fool

Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

February 27, 2025

Via Benzinga

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

February 27, 2025

CATALYST PHARMACEUTICALS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:CPRX showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.